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Abstract
Background: The PCK1 gene, encoding cytosolic phosphoenolpyruvate carboxykinase (PEPCK-
C), has previously been implicated as a candidate gene for type 2 diabetes (T2D) susceptibility.
Rodent models demonstrate that over-expression of Pck1 can result in T2D development and a
single nucleotide polymorphism (SNP) in the promoter region of human PCK1 (-232C/G) has
exhibited significant association with the disease in several cohorts. Within the UK-resident South
Asian population, T2D is 4 to 6 times more common than in indigenous white Caucasians. Despite
this, few studies have reported on the genetic susceptibility to T2D in this ethnic group and none
of these has investigated the possible effect of PCK1 variants. We therefore aimed to investigate
the association between common variants of the PCK1 gene and T2D in a UK-resident South Asian
population of Punjabi ancestry, originating predominantly from the Mirpur area of Azad Kashmir,
Pakistan.
Methods: We used TaqMan assays to genotype five tagSNPs covering the PCK1 gene, including the
-232C/G variant, in 903 subjects with T2D and 471 normoglycaemic controls.
Results: Of the variants studied, only the minor allele (G) of the -232C/G SNP demonstrated a
significant association with T2D, displaying an OR of 1.21 (95% CI: 1.03 - 1.42, p = 0.019).
Conclusion: This study is the first to investigate the association between variants of the PCK1 gene
and T2D in South Asians. Our results suggest that the -232C/G promoter polymorphism confers
susceptibility to T2D in this ethnic group.
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Background
Cytosolic phosphoenolpyruvate carboxykinase (PEPCK-
C), encoded by the PCK1 gene in humans, is an enzyme
centrally involved in gluconeogenesis, glyceroneogenesis
and cataplerosis. Normal expression of PCK1  is under
hormonal control, regulated at the transcriptional level by
both activators, such as glucagon, and inhibitors, such as
insulin. The metabolic functions of PEPCK-C advocate the
PCK1 gene as a strong candidate for conferring suscepti-
bility to type 2 diabetes (T2D), a theory that is supported
by the effects of gene modulation in mouse and rat mod-
els. These include over-expression of PEPCK-C resulting in
insulin resistance and T2D [1].
Genetic studies have previously implicated the region of
chromosome 20q in which PCK1 lies in T2D susceptibil-
ity [2,3]. Cao et al. [4] reported on the discovery of a single
nucleotide polymorphism (SNP) in the promoter region
of PCK1 (-232C/G) that was associated with T2D in Cana-
dian Caucasian and Oji-Cree cohorts (odds ratio (OR) =
2.8, 95% CI 1.7 - 4.7, p = 4 × 10-5 and OR = 1.9, 95% CI
1.2 - 3.0, p = 9 × 10-3 respectively). In addition, luciferase
reporter assays demonstrated that the -232G allele
increased expression of PCK1  compared to the -232C
allele in multiple cell lines, with no down regulation by
insulin. As with many genetic association studies investi-
gating polygenic diseases, attempts to replicate the associ-
ation between PCK1  and T2D have produced mixed
results. A haplotype of PCK1 variants was shown to confer
risk of developing the disease in a Korean population (OR
not given, p = 6 × 10-3) [5], and a screen of 134 candidate
susceptibility SNPs showed that the -232C/G SNP was a
risk factor for T2D in a Finnish cohort (OR = 1.27, 95% CI
1.02 - 1.57, p = 0.031) [6]. A recent study reported that
multiple PCK1 variants are associated with T2D in a Chi-
nese population [7]. The authors of this paper reported -
232C as a risk allele, although its association with the dis-
ease fell short of statistical significance (OR = 1.24, 95%
CI 1.00 - 1.55, p = 0.057). Studies investigating other pop-
ulations, however, have found no evidence for an associ-
ation between PCK1 variants and T2D [8,9].
Within the UK, T2D is 4 to 6 times more common in the
South Asian population compared to the indigenous
white Caucasian population [10]. Over 10% of South
Asian adults will develop the disease and yet only a small
number of investigations have reported on the genetic
susceptibility to T2D in this ethnic group. None of these
studies has looked into the possible effects of the PCK1
gene. We therefore aimed to investigate the association
between common variants of the PCK1 gene and T2D in a
UK-resident South Asian population of Punjabi ancestry.
Methods
Type 2 diabetic subjects (N = 903) were recruited to the
United Kingdom Asian Diabetes Study (UKADS), a multi-
ple risk factor intervention trial investigating the impact of
a culturally-sensitive, enhanced diabetes care package on
the risk of cardiovascular disease in South Asian type 2
diabetes patients living in Birmingham and Coventry, UK
[11]. All subjects were of Punjabi ancestry, confirmed over
three generations, and originated predominantly from the
Mirpur area of Azad Kashmir, Pakistan. Ethnically-
matched normoglycaemic control subjects (N = 471) were
recruited from the same geographical areas through com-
munity screening. Normal glucose tolerance was defined
as fasting plasma glucose <6 mmol/l and 2 hr plasma glu-
cose <7.8 mmol/l on a 75 g OGTT. Where OGTT was not
feasible, normal glucose tolerance was defined as random
blood glucose <7 mmol/l. Venous blood was collected
from each subject after obtaining informed consent and
genomic DNA extracted using an adaptation of the
Nucleon®  protocol (Nucleon Biosciences, Coatbridge,
UK). The study was approved by the Birmingham East,
North and Solihull Research Ethics Committee.
SNP selection and genotyping
In addition to investigating the -232C/G promoter poly-
morphism (rs2071023), we also utilised Haploview 3.2
[12] to tag SNPs within the entire PCK1 gene. To do this
we used data from the CEPH (CEU) HapMap samples
(Utah residents with ancestry from northern and western
Europe)[13], as this population was the closest proxy for
our South Asian population available on the HapMap at
the time tag SNPs were chosen. Our criteria for tagging
SNPs were r2 ≥ 0.7 and a minor allele frequency (MAF) ≥
0.15, using pairwise tagging only. This resulted in four
extra SNPs (rs6070157, rs2070756, rs2179706 and
rs1042531) for analysis. All SNPs were genotyped using
TaqMan SNP Genotyping assays (Applied Biosystems,
Warrington, UK) and fluorescence was measured using an
ABI 7900 sequence detection system (Applied Biosys-
tems).
Statistical analyses
Genotype frequencies for each SNP were checked for
Hardy-Weinberg equilibrium using a chi square good-
ness-of-fit test. Pairwise linkage disequilibrium (LD)
between SNPs was estimated using Haploview version
3.2. Variants were tested for association with type 2 diabe-
tes using logistic regression, assuming an additive genetic
model. Possible confounding variables (BMI, gender,
family history of T2D) were initially included in the logis-
tic regression as covariates. Haplotype analyses were per-
formed using Haploview version 3.2. Association between
genotypes and continuous variables was tested using anal-
ysis of variance (ANOVA). The significance of the relation-
ship between OR and minimum age threshold was
determined using linear regression. All of the above statis-
tical analyses were implemented in SPSS version 13.0
(SPSS Inc, Chicago IL). Power calculations were per-
formed using Genetic Power Calculator [14].BMC Medical Genetics 2009, 10:83 http://www.biomedcentral.com/1471-2350/10/83
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Results
The clinical characteristics of the subjects in our study are
shown in Table 1. Age of diagnosis, HDL cholesterol and
HbA1c data were available for subjects with diabetes only,
whereas BMI, waist circumference and blood pressure
measurements were available for both the diabetic group
and a maximum of 279 subjects from the control group.
Genotypes of the studied PCK1  SNPs were not signifi-
cantly associated with any clinical, biochemical or mor-
phological characteristic measured (Table 2).
LD patterns (Figure 1) and allele frequencies for all vari-
ants were generally similar to those seen in the CEPH
(CEU) HapMap samples (CEU allele frequencies:
rs2071023 (G) - 0.52, rs6070157 (T) - 0.21, rs2070756
(T) - 0.25, rs2179706 (T) - 0.52, rs1042531 (G) - 0.31).
Genotyping success rate was ≥ 97.5% for all SNPs studied.
Approximately 15% of all individuals were re-genotyped
for the estimation of error rate, which was <1% for all var-
iants. All SNPs conformed to Hardy-Weinberg equilib-
rium with the exception of rs6070157 (p = 0.01). As the
error rate for this SNP was zero and it displayed no signif-
icant association with any variable measured, no further
action was taken to investigate this anomaly.
Of the variants studied, only the minor allele of
rs2071023 displayed a significant association with T2D,
with an OR of 1.21 (95% CI 1.03 - 1.42, p = 0.019; Table
3). A number of clinical and morphological characteristics
(gender, BMI, family history of T2D) were included as
covariates in our initial analyses, but had no qualitative
effect on the observed association and so were excluded
from the final model. As statistical power was low for all
variants (≤ 72% power to reject a false negative for all var-
iants), we cannot categorically state that the other SNPs
studied confer no susceptibility to T2D. We have previ-
ously confirmed that variants of TCF7L2 confer suscepti-
bility to T2D in this population [15]. Genotype of the
TCF7L2  SNP rs7903146 was therefore included in the
logistic regression model as a covariate, but had no effect
on the results and so was excluded from the final model.
Only one haplotype, comprising the rs2071023 G allele
and the rs6070157 C allele, was significantly associated
with T2D (Haplotype 1; OR = 1.20, p = 0.024; Table 4).
This was the only haplotype to contain the rs2071023 G
allele and the effect on disease risk was similar to that of
rs2071023 alone, suggesting that the haplotype associa-
tion was due solely to the rs2071023 SNP.
Including young control subjects within a case-control
analysis can artificially reduce effect size and statistical sig-
nificance, as it can increase the chance of including sub-
jects who will develop T2D later in life. As we have done
previously with TCF7L2  [15], we re-analyzed our data
using subsets of the control group defined by different
minimum age cut-offs. For SNP rs2071023 there was a
significant relationship between control-group minimum
age cut-off and both OR (r2 = 0.912, p = 3.86 × 10-7) and
statistical significance of the logistic regression test (r2 =
Table 1: Clinical characteristics of subjects studied
Diabetic subjects Control subjects
Male Female Male Female
n 494 409 230 241
Age at study (years) 57.1 ± 11.9 56.7 ± 12.3 57.1 ± 11.8 53.0 ± 11.6
Age at diagnosis (years) 49.8 ± 11.7 49.3 ± 12.3 NAa NAa
BMI (kg/m2) 27.4 ± 4.1 30.0 ± 4.9 27.1 ± 4.1 28.9 ± 5.3
Waist circumference (cm)c 100.9 ± 10.1 104.2 ± 11.0 100.5 ± 11.2 99.0 ± 13.8
Systolic blood pressure (mm Hg)c 141.4 ± 19.3 138.9 ± 22.5 139.5 ± 19.6 131.1 ± 20.2
Diastolic blood pressure (mm Hg) 84.5 ± 12.6 84.1 ± 12.0 86.0 ± 11.6 82.9 ± 12.1
HDL cholesterol (mmol/l) 1.3 ± 0.6 1.3 ± 0.4 NDb NDb
HbA1c (%) 8.3 ± 2.0 8.3 ± 1.7 NDb NDb
Data are expressed as means ± SD. aNA = not applicable. bND = not determined. c = significant difference between diabetic and control groups (t-
test; p < 0.01).BMC Medical Genetics 2009, 10:83 http://www.biomedcentral.com/1471-2350/10/83
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0.838, p = 1.12 × 10-5), up until maximum statistical sig-
nificance (minimum p-value) was reached at an age cut-
off of 47 years. At this age cut-off the effect size of the asso-
ciation had greatly increased (OR = 1.31, 95% CI 1.10 -
1.56, p = 2 × 10-3), remaining significant even after correct-
ing for multiple testing (Bonferroni correction for testing
5 SNPs, p = 0.015). After this age cut-off both relation-
ships began to deteriorate as the number of individuals
within the control group was further reduced. It is interest-
ing to note that when an age cut-off of 47 years was
applied to the control group, statistical power actually
increased to 90% due to the increase in OR, despite a drop
in subject numbers.
Discussion
As previously reported in a number of studies[4,6] our
results suggest that the -232C/G SNP (rs2071023) located
Table 2: Clinical characteristics of subjects studied
Diabetic subjects Control subjects
rs2071023 CC CG GG CC CG GG
BMI (kg/m2) 28.8 ± 4.6 28.4 ± 4.7 28.9 ± 4.7 28.5 ± 5.2 27.7 ± 4.8 28.3 ± 4.1
Waist circumference (cm) 102.8 ± 10.5 102.1 ± 11.0 103.0 ± 10.0 100.1 ± 13.4 98.8 ± 11.5 101.5 ± 13.7
Systolic blood pressure (mm Hg) 140.6 ± 20.6 139.7 ± 20.1 141.1 ± 22.7 134.4 ± 19.3 135.2 ± 20.5 136.3 ± 22.2
Diastolic blood pressure (mm Hg) 84.0 ± 11.5 84.2 ± 13.2 85.2 ± 11.8 84.8 ± 11.2 84.2 ± 12.2 84.1 ± 12.7
HDL cholesterol (mmol/l) 1.3 ± 0.5 1.3 ± 0.5 1.3 ± 0.5 ND ND ND
HbA1c (%) 8.3 ± 1.8 8.2 ± 1.8 8.4 ± 2.1 ND ND ND
rs6070157 CC CT TT CC CT TT
BMI (kg/m2) 28.6 ± 4.7 28.6 ± 4.8 28.0 ± 3.4 28.0 ± 4.7 28.1 ± 5.0 28.7 ± 5.3
Waist circumference (cm) 102.5 ± 10.3 102.4 ± 11.0 102.0 ± 13.4 99.5 ± 13.0 99.0 ± 12.1 103.8 ± 10.4
Systolic blood pressure (mm Hg) 140.1 ± 20.9 140.5 ± 20.5 139.3 ± 19.9 133.9 ± 20.5 136.6 ± 20.1 139.6 ± 20.3
Diastolic blood pressure (mm Hg) 84.3 ± 11.7 84.6 ± 14.4 83.9 ± 7.9 83.6 ± 12.0 85.5 ± 12.3 86.4 ± 9.9
HDL cholesterol (mmol/l) 1.3 ± 0.5 1.3 ± 0.5 1.2 ± 0.3 ND ND ND
HbA1c (%) 8.4 ± 2.0 8.2 ± 1.7 8.0 ± 1.6 ND ND ND
rs2070756 CC CT TT CC CT TT
BMI (kg/m2) 28.5 ± 4.5 28.7 ± 4.8 28.3 ± 4.5 28.0 ± 4.9 27.9 ± 4.8 29.1 ± 5.0
Waist circumference (cm) 102.2 ± 10.7 102.8 ± 10.6 102.3 ± 10.2 99.4 ± 12.3 99.3 ± 12.9 102.7 ± 13.8
Systolic blood pressure (mm Hg) 139.6 ± 20.5 141.8 ± 21.6 138.7 ± 19.1 134.7 ± 20.3 136.9 ± 20.7 132.8 ± 19.5
Diastolic blood pressure (mm Hg) 84.7 ± 13.0 84.3 ± 12.0 83.5 ± 10.4 84.8 ± 11.5 84.0 ± 12.0 84.1 ± 14.2
HDL cholesterol (mmol/l) 1.3 ± 0.5 1.3 ± 0.5 1.3 ± 0.4 ND ND ND
HbA1c (%) 8.2 ± 1.9 8.3 ± 1.8 8.5 ± 2.1 ND ND ND
rs2179706 CC CT TT CC CT TT
BMI (kg/m2) 28.7 ± 4.9 28.5 ± 4.6 28.5 ± 4.4 28.5 ± 4.6 27.8 ± 4.8 27.8 ± 5.1
Waist circumference (cm) 103.0 ± 10.5 102.0 ± 10.7 102.4 ± 10.8 102.6 ± 13.8 98.1 ± 11.7 98.3 ± 12.1
Systolic blood pressure (mm Hg) 141.2 ± 20.8 140.2 ± 21.7 139.2 ± 18.7 134.4 ± 21.0 135.0 ± 19.6 137.0 ± 21.0
Diastolic blood pressure (mm Hg) 84.8 ± 11.1 83.9 ± 13.9 85.3 ± 10.5 83.5 ± 12.2 85.1 ± 12.0 84.7 ± 11.0
HDL cholesterol (mmol/l) 1.3 ± 0.5 1.3 ± 0.5 1.2 ± 0.3 ND ND ND
HbA1c (%) 8.4 ± 2.0 8.3 ± 1.8 8.0 ± 1.7 ND ND ND
rs1042531 TT GT GG TT GT GG
BMI (kg/m2) 28.4 ± 4.4 28.9 ± 4.8 28.4 ± 5.2 28.2 ± 5.1 27.5 ± 4.6 29.1 ± 4.0
Waist circumference (cm) 102.2 ± 10.2 103.1 ± 11.0 101.3 ± 11.2 99.7 ± 13.0 99.1 ± 11.3 101.5 ± 17.1
Systolic blood pressure (mm Hg) 139.2 ± 20.3 140.2 ± 20.6 144.5 ± 22.8 135.9 ± 20.0 136.1 ± 20.2 128.3 ± 22.2
Diastolic blood pressure (mm Hg) 83.6 ± 11.0 84.8 ± 14.1 85.8 ± 10.4 85.4 ± 11.6 84.0 ± 12.2 82.4 ± 12.5
HDL cholesterol (mmol/l) 1.3 ± 0.4 1.3 ± 0.5 1.3 ± 0.6 ND ND ND
HbA1c (%) 8.2 ± 1.8 8.3 ± 1.8 8.5 ± 2.4 ND ND ND
Genotypes of the studied PCK1 variants were not significantly associated with any measured clinical characteristic (ANOVA; p > 0.05 for all tests). 
Data are expressed as means ± SD. ND = not determined.BMC Medical Genetics 2009, 10:83 http://www.biomedcentral.com/1471-2350/10/83
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in the promoter region of the PEPCK-C-encoding PCK1
gene is associated with T2D.
It has been suggested that T2D could be caused by either
excessive PEPCK-C production in the liver or reduced lev-
els of PEPCK-C in adipose tissue [16]. In addition, from
expression analysis of luciferase reporter constructs in
multiple cell lines, Cao et al. [4] demonstrated that the -
232G risk allele resulted in increased basal gene expres-
sion when compared to the -232C allele. It is possible,
therefore, that the -232C/G polymorphism may confer
increased risk of T2D development by increasing PCK1
expression in the liver. This would result in an upregula-
tion of gluconeogenesis and increased blood glucose lev-
els. Unfortunately we were not able to investigate the
relationship between PCK1 genotype and blood glucose
levels in this study, as fasting blood glucose data were
only available for a small subset of our control subjects.
Interestingly, a recent study has shown that liver-specific
silencing of Pck1 can improve glycaemic control and insu-
lin sensitivity in a T2D mouse model [17], supporting the
role of PEPCK-C in T2D pathology and providing a poten-
tial therapeutic target for treatment of the disease.
Although the use of our entire cohort resulted in an OR of
1.21, the removal of young control subjects should have
increased the validity of the control group. The OR of 1.31
resulting from our reduced dataset, similar to that seen in
a Finnish cohort (OR = 1.27) [6], may therefore be a more
representative estimate of the true effect size of this SNP,
Pairwise linkage disequilibrium (LD) in CEPH (CEU) HapMap samples and the Pakistani study population Figure 1
Pairwise linkage disequilibrium (LD) in CEPH (CEU) HapMap samples and the Pakistani study population. LD 
expressed as D' and r2 for the CEPH (CEU) HapMap samples and the Pakistani study population. Blank squares equate to a D' 
value of 1.
(a) CEPH (CEU) HapMap (D’)  (b) CEPH (CEU) HapMap (r
2) 
(c) Pakistani study population (D’)  (d) Pakistani study population (r
2) BMC Medical Genetics 2009, 10:83 http://www.biomedcentral.com/1471-2350/10/83
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one that is not inconsiderable compared to recently dis-
covered T2D susceptibility variants.
There are a number of limiting factors to be considered
when interpreting our results. Firstly, our cohort is limited
in size. Secondly, there is the possibility of cryptic related-
ness within our cohort as the study subjects were recruited
from a relatively small migrant population. In addition to
this consanguinity is relatively common in the Mirpuri
population. These limitations increase the risk of our
result being a false positive. Unfortunately we cannot con-
trol for relatedness in our analyses as we do not have the
necessary data. The impact of cryptic relatedness on asso-
ciation studies, however, increases with sample size [18],
so it may be that our relatively small cohort is to some
degree protected from this effect. Furthermore, we have
no reason to believe that the degree of relatedness would
differ significantly between the diabetic and control
groups and so the effect of any cryptic relatedness may be
negated.
Conclusion
This study is the first to investigate the association
between variants of the PCK1  gene and T2D in South
Asians. In agreement with studies in other ethnic groups
[4,6], our analyses suggest that the -232C/G promoter
SNP (rs2071023) confers susceptibility to T2D. Due to the
limitations discussed within this manuscript, however, we
cannot exclude the possibility that our findings are a false
positive result. We strongly advocate that replication of
Table 3: Association of PCK1 variants with type 2 diabetes among UK-resident South Asians
SNP Gene Region Allele Diabetic
 subjects Fa
Control 
subjects Fa
Genotype Diabetic 
subjects n (%)b
Control 
subjects n (%)b
Allelic ORc 
(95% CI)
rs2071023 Promoter C 0.53 0.57 CC 243 (0.27) 158 (0.34) 1.21
CG 447 (0.51) 225 (0.48) (1.03 - 1.42)
G 0.47 0.43 GG 195 (0.22) 88 (0.19) p = 0.019
rs6070157 Exon 3 C 0.81 0.79 CC 597 (0.67) 305 (0.65) 0.90
CT 258 (0.29) 135 (0.29) (0.74 - 1.08)
T 0.19 0.21 TT 38 (0.04) 29 (0.06) p = 0.257
rs2070756 Exon 7 C 0.72 0.71 CC 456 (0.52) 246 (0.53) 1.00
CT 354 (0.40) 171 (0.37) (0.84 - 1.18)
T 0.28 0.29 TT 75 (0.08) 47 (0.10) p = 0.965
rs2179706 Intron 8 C 0.58 0.56 CC 298 (0.34) 156 (0.34) 0.92
CT 424 (0.48) 206 (0.45) (0.79 - 1.08)
T 0.42 0.44 TT 156 (0.18) 100 (0.22) p = 0.323
rs1042531 3'UTR T 0.66 0.68 TT 391 (0.44) 206 (0.45) 1.06
GT 384 (0.44) 212 (0.46) (0.89 - 1.25)
G 0.34 0.32 GG 104 (0.12) 44 (0.10) p = 0.528
aF = Allele frequency. bGenotype frequency expressed as number of individuals, n - values in parentheses indicate percentage. cOR = odds ratio, 
95% CI = 95% confidence interval. Allelic OR refers to the risk associated with a single copy of the risk allele. All values were calculated using the 
full dataset, the minimum age of control subjects being 35 years.
Table 4: Association of PCK1 haplotypes with type 2 diabetes among UK-resident South Asians
LD Block Haplotype SNP1 SNP2 SNP3 SNP4 Diabetic subjects Fa Control subjects Fa Odds ratio (OR) p
1 Haplotype 1 G C - - 0.472 0.427 1.20 0.024
1 Haplotype 2 C C - - 0.341 0.369 0.89 0.150
1 Haplotype 3 C T - - 0.185 0.204 0.89 0.239
2 Haplotype 4 - - C T 0.405 0.417 0.95 0.538
2 Haplotype 5 - - C C 0.311 0.297 1.06 0.475
2 Haplotype 6 - - T C 0.271 0.264 1.03 0.710
2 Haplotype 7 - - T T 0.014 0.021 0.63 0.130
aF = Haplotype frequency. All values were calculated using the full dataset, the minimum age of control subjects being 35 years. SNP1 = rs2071023, 
SNP2 = rs6070157, SNP3 = rs2070756, SNP4 = rs2179706.Publish with BioMed Central    and   every 
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this association in larger independent South Asian cohorts
is needed to confirm the -232C/G polymorphism of PCK1
as a true T2D susceptibility variant in this ethnic group.
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